Sanna Bastiano

SEC source: 0001209191-23-046097 · doc4.xml · derivative · entry 10

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,400

Underlying: Common Stock · 26,400 shares

Expires 2033-05-31

F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F6 · derivative.exercise_date: The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.

SEC source: 0001209191-23-046097 · doc4.xml · derivative · entry 9

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,400 shares

Expires 2033-05-31

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F6 · derivative.exercise_date: The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.

SEC source: 0001209191-23-046097 · doc4.xml · derivative · entry 8

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2032-06-01

F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0001209191-23-046097 · doc4.xml · derivative · entry 7

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,500 shares

Expires 2032-06-01

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0001209191-23-046097 · doc4.xml · derivative · entry 6

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,172

Underlying: Common Stock · 1,172 shares

Expires 2031-04-29

F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F5 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on December 1, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.

SEC source: 0001209191-23-046097 · doc4.xml · derivative · entry 5

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,172 shares

Expires 2031-04-29

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F5 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on December 1, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.

SEC source: 0001209191-23-046097 · doc4.xml · derivative · entry 4

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2031-04-29

F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0001209191-23-046097 · doc4.xml · derivative · entry 3

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,500 shares

Expires 2031-04-29

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0001209191-23-046097 · doc4.xml · derivative · entry 2

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,828

Underlying: Common Stock · 28,828 shares

Expires 2030-11-30

F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: 33% of the shares subject to this option vested and became exercisable on December 1, 2021, with the remaining 67% vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.

SEC source: 0001209191-23-046097 · doc4.xml · derivative · entry 1

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,828 shares

Expires 2030-11-30

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: 33% of the shares subject to this option vested and became exercisable on December 1, 2021, with the remaining 67% vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.

SEC source: 0001209191-23-033960 · doc4.xml · derivative · entry 2

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,400

Underlying: Common Stock · 26,400 shares

Expires 2033-05-31

F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0001209191-23-033960 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,900

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0001209191-23-028243 · doc4.xml · nonDerivative · entry 2

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,038

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

SEC source: 0001209191-23-028243 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,888

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $350.03 (range $350.00 to $350.40).

SEC source: 0001209191-23-027374 · doc4.xml · nonDerivative · entry 5

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,310

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F7 · price: Open market sales reported on this line occurred at a weighted average price of $351.60 (range $351.01 to $352.00).

SEC source: 0001209191-23-027374 · doc4.xml · nonDerivative · entry 4

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,038

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F6 · price: Open market sales reported on this line occurred at a weighted average price of $350.44 (range $350.00 to $350.94).

SEC source: 0001209191-23-027374 · doc4.xml · nonDerivative · entry 3

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,091

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F5 · price: Open market sales reported on this line occurred at a weighted average price of $353.24 (range $353.21 to $353.49).

SEC source: 0001209191-23-027374 · doc4.xml · nonDerivative · entry 2

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,260

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $351.65 (range $351.48 to $351.80).

SEC source: 0001209191-23-027374 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,302

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $350.32 (range $350.00 to $350.92).

SEC source: 0001209191-23-024312 · doc4.xml · nonDerivative · entry 3

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,713

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F5 · price: Open market sales reported on this line occurred at a weighted average price of $327.43 (range $327.01 to $327.91).

SEC source: 0001209191-23-024312 · doc4.xml · nonDerivative · entry 2

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,338

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $326.45 (range $326.00 to $326.99).

SEC source: 0001209191-23-024312 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,406

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $325.70 (range $325.00 to $325.98).

SEC source: 0001209191-23-023588 · doc4.xml · nonDerivative · entry 5

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,280

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

SEC source: 0001209191-23-023588 · doc4.xml · nonDerivative · entry 4

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,311

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F6 · price: Open market sales reported on this line occurred at a weighted average price of $317.65 (range $317.49 to $317.74).

SEC source: 0001209191-23-023588 · doc4.xml · nonDerivative · entry 3

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,407

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F5 · price: Open market sales reported on this line occurred at a weighted average price of $316.76 (range $316.41 to $317.20).

SEC source: 0001209191-23-023588 · doc4.xml · nonDerivative · entry 2

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,497

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $315.66 (range $315.08 to $315.96).

SEC source: 0001209191-23-023588 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,591

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $314.22 (range $313.72 to $314.70).

SEC source: 0001209191-23-022695 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,802

SEC source: 0001209191-23-020043 · doc4.xml · nonDerivative · entry 2

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,268

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was adopted on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $301.07 (range $301.00 to $301.14).

SEC source: 0001209191-23-020043 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,532

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was adopted on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $300.54 (range $300.00 to $300.94).

SEC source: 0001209191-23-013757 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,014

SEC source: 0001209191-23-011701 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,984

SEC source: 0001209191-23-010055 · doc4.xml · nonDerivative · entry 2

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,734

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $301.11 (range $301.02 to $301.22).

SEC source: 0001209191-23-010055 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,013

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $300.29 (range $300.00 to $300.92).

SEC source: 0001209191-23-009232 · doc4.xml · nonDerivative · entry 3

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,915

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $300.39 (range $300.00 to $300.79).

SEC source: 0001209191-23-009232 · doc4.xml · nonDerivative · entry 2

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,028

SEC source: 0001209191-23-009232 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,368

SEC source: 0001209191-23-006980 · doc4.xml · nonDerivative · entry 3

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,270

F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024.

SEC source: 0001209191-23-006980 · doc4.xml · nonDerivative · entry 2

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,404

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023.

SEC source: 0001209191-23-006980 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,090

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 03/01/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023.

SEC source: 0001209191-23-006215 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,998

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.

SEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 8

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,104

F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1.

F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.

F8 · price: Open market sales reported on this line occurred at a weighted average price of $317.77 (range $317.56 to $317.82).

SEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 7

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,126

F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1.

SEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 6

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,136

F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1.

F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.

F7 · price: Open market sales reported on this line occurred at a weighted average price of $314.43 (range $314.42 to $314.48).

SEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 5

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,148

F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1.

F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.

F6 · price: Open market sales reported on this line occurred at a weighted average price of $313.37 (range $312.98 to $313.97).

SEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 4

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,229

F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1.

F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.

F5 · price: Open market sales reported on this line occurred at a weighted average price of $312.40 (range $311.98 to $312.90).

SEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 3

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,329

F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1.

F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $311.17 (range $310.51 to $311.45).

SEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 2

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,368

F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1.

F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $310.10 (range $309.50 to $310.48).

SEC source: 0000899243-22-034883 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,424

SEC source: 0000899243-22-033880 · doc4.xml · nonDerivative · entry 2

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,192

F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1.

F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $301.84 (range $301.14 to $301.98).